Insider filing
Traded Jan 6 · filed 2 days later
Routine share withholding; mechanical by default.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Dec 17, 2025 · Filed Dec 18, 2025
Incyte's Head of Tech. Operations sold $420K of Incyte shares. The filing references vesting of compensation awards.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$420,455
Shares × reported transaction price
50 days after results of Oct 28, 2025, 55 days before results of Feb 10, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $97.63 on Dec 17, 2025, 77% above its 52-week low and 10% below its high, after a 5% drop over the previous 30 trading days
52-week range $55.17 (Apr 10, 2025) to $108.26 (Nov 12, 2025), 80% of the way up, from 250 adjusted closes. 30 trading days earlier: $102.92 on Nov 4, 2025. Describes the past only, not a forecast
RSI 47, 26% above its 200-day average, at its 50-day average, 10% below the 52-week high, 20-day volatility 34% a year, against the S&P 500: −7 points over 1 month, +12 points over 3 months, +31 points over 6 months
From the adjusted closes up to Dec 17, 2025. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
FDA approved Zynyz on Dec 17, 2025, the same day as this trade.
New use approved (efficacy supplement). Active ingredient: Retifanlimab-Dlwr. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −2.5% | +1.4% | −3.9% |
| 30 days | −0.1% | −0.4% | +0.4% |
| 90 days | −9.5% | −3.0% | −6.4% |
| 180 days | −3.6% | +8.9% | −12.5% |
Past results only. Not a forecast.
Insider filing
Traded Jan 6 · filed 2 days later
Routine share withholding; mechanical by default.
Mohamed Khairie Issa (EVP, Head of US Oncology) sold ~$1.18M of Incyte
Automatic saleSteven H Stein (EVP & Chief Medical Officer) sold ~$1.59M of Incyte
Automatic saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.